Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • cnicolet
    Member
    • Dec 2008
    • 35

    Nextera exome kit

    Hi:
    Recently we tested the nextera exome enrichment libe kit. In our analysis pipeline we have a metric that calculates exonic reads, intronic reads, and intergenic reads. Our nextera libes all had about 50% match to the exons. That seemed low, I went back and looked at the same metric from the original illumina kits, those also had only about 50% exonic reads. Does this seem low? It throws a real wrench into coverage calculations
  • Bukowski
    Senior Member
    • Jan 2010
    • 388

    #2
    What is the on-target specification of Nextera? I don't use Nextera, I use SureSelect, which will generally give ~65% 'on target' reads on variable quality samples, but the Agilent literature claims 70%. For custom capture regions on SureSelect, 50% on target is all you will get, so it depends. Also are you feeding a list of all exons to your coverage metric calculator? Or just the exons in the capture kit?

    Comment

    • cnicolet
      Member
      • Dec 2008
      • 35

      #3
      Thanks for your comments. That is an excellent point, I'm sure we are feeding all known exons so that could be a big part of it. I'll know a lot more when we send the sureselect material info through the same pipeline, but it does sound as though those numbers are to be expected. Just looking around on the browser it is clear that are abundant areas of off target seqeuncing.

      Comment

      • Genohub
        Registered Vendor
        • Mar 2013
        • 210

        #4
        We've outlined each currently available capture technology in a comparison table here:
        Whole exome sequencing services guide compares exome capture kits, demonstrates how to calculate the reads required to meet coverage requirements and makes best practice recommendations.


        In our guide for determining the number of sequencing reads one needs for a targeted capture expt, we estimate on-target rates to be between 65-75%. I'd be interested in hearing other people's experiences and their rates.

        - Genohub

        Comment

        • evakoe
          Member
          • Jul 2012
          • 27

          #5
          In my lab we are using the Nextera Rapid Capture Exome kit and I also get only slightly above 50% of all reads mapping on the target region. Unfortunately, this number has been low and stable over multiple runs. In my experience, the on-target or coverage estimations given by the vendors are always to high and cannot be reproduced.

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
            by SEQadmin2


            Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

            The systematic characterization of the human proteome has
            ...
            07-20-2026, 11:48 AM
          • SEQadmin2
            Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
            by SEQadmin2



            Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
            ...
            07-09-2026, 11:10 AM
          • SEQadmin2
            Cancer Drug Resistance: The Lingering Barrier to Rising Survival
            by SEQadmin2



            Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

            There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
            07-08-2026, 05:17 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, 07-24-2026, 12:17 PM
          0 responses
          21 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-23-2026, 11:41 AM
          0 responses
          19 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-20-2026, 11:10 AM
          0 responses
          26 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-13-2026, 10:26 AM
          0 responses
          38 views
          0 reactions
          Last Post SEQadmin2  
          Working...